Advances in the treatment of neuromyelitis optica spectrum disorder

AI Wallach, M Tremblay, I Kister - Neurologic Clinics, 2021 - neurologic.theclinics.com
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing-remitting
neuroinflammatory disorder of the central nervous system (CNS) usually associated with …

Current trends and challenges in the mitoxantrone measuring in biofluids and new pharmaceutical systems

OA Goryacheva, PS Pidenko, AV Markin… - TrAC Trends in …, 2023 - Elsevier
Adaptation of medical treatment to a particular patient requires the monitoring the
concentration of active substances or biomarkers in the body during medical treatment …

Treatment and relapse prevention of typical and atypical optic neuritis

G Saitakis, BK Chwalisz - International Journal of Molecular Sciences, 2022 - mdpi.com
Optic neuritis (ON) is an inflammatory condition involving the optic nerve. Several important
typical and atypical ON variants are now recognized. Typical ON has a more favorable …

Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy

Y Takai, H Kuroda, T Misu, T Akaishi… - Multiple Sclerosis and …, 2021 - Elsevier
Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing
neuroinflammatory disease associated with aquaporin-4 antibody. Since disabilities in …

Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy

Y Guan, S Jiang, W Ye, X Ren, X Wang, Y Zhang… - Cell Death & …, 2020 - nature.com
Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and
contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors …

Evidence-based management of optic neuritis

E Bergeron, MA Bouffard - Current Opinion in Ophthalmology, 2024 - journals.lww.com
In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it
does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are …

A Clinical Approach to existing and emerging therapeutics in Neuromyelitis Optica Spectrum Disorder

HYF Yong, JM Burton - Current Neurology and Neuroscience Reports, 2023 - Springer
Abstract Purpose of Review Neuromyelitis optica spectrum disorder (NMOSD) is a rare but
highly disabling disease of the central nervous system. Unlike multiple sclerosis, disability in …

Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta-analysis

Y Wang, H Chang, X Zhang, L Yin - Multiple sclerosis and related disorders, 2021 - Elsevier
Background Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune astrocyte
disease that mainly affects the optic nerve and spinal cord resulting in blindness or …

Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean

H Chaumont, N Bérard, JP Karam… - Neurology …, 2024 - AAN Enterprises
Background and Objectives Preventing relapses in neuromyelitis Optica spectrum disorder
(NMOSD) is a primary goal. New effective molecules are often expensive and not readily …

Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta-analysis

J Ma, H Yu, H Wang, X Zhang, K Feng - Journal of Neuroimmunology, 2022 - Elsevier
Background Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of
the central nervous system, which mainly involves the optic nerve and spinal cord. Frequent …